Zynex (ZYXI)
(Delayed Data from NSDQ)
$10.00 USD
+0.60 (6.38%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $9.98 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Brokerage Reports
Zynex Inc. [ZYXI]
Reports for Purchase
Showing records 41 - 60 ( 94 total )
Company: Zynex Inc.
Industry: Medical - Products
Strong 1Q20 Order Growth; Guidance Raised, Despite Pandemic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
4Q and Full-Year 2019 Financial Results Reported; Reiterate Buy; Raising PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Blood Volume Monitor 510(k) Approval; Reiterate Buy; Raising PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Blood Volume Monitor European Patent Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Preliminary 4Q19 Results; Revenue and EBITDA Guidance Raised; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Top-Line Revenue Grows 45% YoY in 3Q19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
NexWave Orders Grow 95% YoY in 3Q19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
We are initiating coverage with a Buy rating and 12-month price target of $12 per share.
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Dropping coverage due to termination of research services
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Zynex Inc.
Industry: Medical - Products
Upgrading to a Buy rating from Speculative Buy and raising our 12-month price target to $8.00 per share from $6.00
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Zynex Inc.
Industry: Medical - Products
Maintaining Speculative Buy rating and increasing our 12-month price target to $6.00 per share from $5.50
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Zynex Inc.
Industry: Medical - Products
Company: Zynex Inc.
Industry: Medical - Products
Maintaining Speculative Buy rating but reducing our 12-month price target to $5.50 per share
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Zynex Inc.
Industry: Medical - Products
Reported 2Q18 EPS
Provider: Consilium Global Research
Company: Zynex Inc.
Industry: Medical - Products
We believe this is exceptional as growth in this quarter is typically seasonally the lowest.
Provider: Consilium Global Research
Company: Zynex Inc.
Industry: Medical - Products
We are raising our price target and top line estimates following strong results
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A
Company: Zynex Inc.
Industry: Medical - Products
Maintaining Speculative Buy rating and 12-month price target of $6.35 per share reflecting an increase in our 2019 EPS forecast
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Zynex Inc.
Industry: Medical - Products
Company: Zynex Inc.
Industry: Medical - Products
reported 4Q17 EPS
Provider: Consilium Global Research
Company: Zynex Inc.
Industry: Medical - Products
We are raising our price target and estimates following strong results
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A